Additional file 1: Table S1. of The prevalence and impact of childhood sexual abuse on HIV-risk behaviors among men who have sex with men (MSM) in India

Unweighted characteristics by childhood sexual abuse1 (CSA) among 11,788 men who have sex with men in 12 Indian cities. Table S2. Number of HIV risk behaviors and experiences by childhood sexual abuse1 (CSA). Table S3. The relationship between CSA and HIV-related risk score. Table S4. The relationship between CSA and recent and lifetime HIV-related risk behaviors and experiences1. (DOCX 37 kb

Additional file 1: of Design of the Indian NCA study (Indian national collaboration on AIDS): a cluster randomized trial to evaluate the effectiveness of integrated care centers to improve HIV outcomes among men who have sex with men and persons who inject drugs in India

MSM Baseline Survey. This survey was distributed (in local languages) to MSM study sites to gather baseline data on HIV status and risk behaviors. (PDF 4627 kb

Risk Factors of Time to Treatment Failure.

1<p>All adjusted models include treatment condition.</p><p>Table Legend:</p><p>QOL_health: general health perceptions.</p><p>QOL_mental: mental health.</p

ACTG A5175/Pearls trial – Survival probability estimate from randomization to treatment failure by pill count non-adherence (solid line = did not miss any pills; dashed line = missed any pills).

<p>ACTG A5175/Pearls trial – Survival probability estimate from randomization to treatment failure by pill count non-adherence (solid line  =  did not miss any pills; dashed line  =  missed any pills).</p

Baseline Participant Characteristics.

<p>Table Legend:</p><p>QOL_health: general health perceptions.</p><p>QOL_mental: mental health.</p><p>Treatment: Once daily protease inhibitor + nucleoside reverse transcriptase inhibitors: atazanavir + didanosine-EC and emtricitabine.</p><p>Treatment: Once daily non-nucleoside reverse transcriptase inhibitor + nucleoside reverse transcriptase inhibitors: efavirenz + co-formulated emtricitabine-tenofovir-DF.</p><p>Standard of care: efavirenz plus co-formulated lamivudine-zidovudine.</p